LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Elenco Azioni・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Chiusa

SettoreSettore sanitario

10.09 -1.75

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.07

Massimo

10.21

Metriche Chiave
By Trading Economics
Entrata	63M 51M
Vendite	90M 231M
P/E Media del settore	8.326 105.69
Margine di Profitto	22.155
Dipendenti	900
EBITDA	95M 96M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+48.37% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	58M 577M
Apertura precedente	11.84
Chiusura precedente	10.09

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

4.95 / N/A Supporto e resistenza

Emergent BioSolutions Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 nov 2025, 17:45 UTC

Utili

I principali Market Mover

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Utili

I principali Market Mover

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

16 nov 2025, 23:40 UTC

Discorsi di Mercato

Gold Rises on Likely Technical Recovery -- Market Talk

16 nov 2025, 23:36 UTC

Discorsi di Mercato

Nikkei May Edge Lower Amid Lingering Worries Over Elevated Tech Valuations -- Market Talk

16 nov 2025, 23:26 UTC

Discorsi di Mercato

RBA Policy Meetings May Contain a Trap for Traders -- Market Talk

16 nov 2025, 16:20 UTC

Utili

Fed Minutes, Plus Walmart, Target, Home Depot, Nvidia, and More Stocks to Watch This Week -- Barrons.com

15 nov 2025, 09:20 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

15 nov 2025, 09:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

15 nov 2025, 00:08 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov 2025, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Discorsi di Mercato

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Utili

Acquisizioni, Fusioni, Takeovers

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Utili

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Discorsi di Mercato

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Acquisizioni, Fusioni, Takeovers

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Discorsi di Mercato

Utili

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Discorsi di Mercato

Utili

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Discorsi di Mercato

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Discorsi di Mercato

Utili

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Discorsi di Mercato

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Discorsi di Mercato

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

Confronto tra pari

Modifica del prezzo

Emergent BioSolutions Inc Previsione

Obiettivo di Prezzo

By TipRanks

48.37% in crescita

Previsioni per 12 mesi

Media 15 USD 48.37%

Alto 15 USD

Basso 15 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Emergent BioSolutions Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Emergent BioSolutions Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.95 / N/ASupporto e resistenza

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.